Aelis Farma S.A. (AELIS.PA)
Aelis Farma S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bordeaux, NA, FR. The stock last traded at $1.02, up 0.00% on the session, giving a market capitalisation of $13.9M. Its beta of 0.62 implies it has historically moved less than the broad market.
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
Aelis Farma S.A. is most often compared with the following Healthcare names: